Skip to main content
. 2014 May 30;16(3):R56. doi: 10.1186/bcr3667

Figure 7.

Figure 7

ARHI reverses JMJD2A-induced tumor progression in vitro. MDA-MB-231 cells and MCF-7 cells were transfected with empty vetor, pcDNA3.1-JMJD2A plasmid, and pcDNA3.1-JMJD2A&pcDNA3.1-ARHI plasmids in advance. (A, E) ARHI reversed JMJD2A-mediated cell proliferation by day 2 and inhibited JMJD2A-mediated proliferation by up to 40% in MDA-MB-231 cells (A) and 33% in MCF-7 cells (E) on day 4. (B, F) Two cell lines were analyzed using a wound-healing assay. Motility was compared between different groups. At 24 h ARHI slowed down JMJD2A-promoted motility in MDA-MB-231 cells (B). At 36 h ARHI slowed down JMJD2A-promoted motility in MCF-7 cells (F); magnification 200×. (C, G) A transwell assay was performed on MDA-MB-231 cells (C) and MCF-7 cells (G). ARHI was observed to attenuate JMJD2A-promoted migration and invasion ability; scale bar = 20 μm. (D, H) The transwell assay was photographed and migrated/invaded cell numbers of five random regions were counted to calculate the average number of cells that transmigrated. *P <0.05, **P <0.01. ARHI, Aplasia Ras homolog member I.